What is the dose of phytonadione (vitamin K1) for bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Phytonadione (Vitamin K1) Dosing for Bleeding

For bleeding due to excessive anticoagulation, the recommended dose of phytonadione (vitamin K1) is 5-10 mg intravenously for significant bleeding, with 10 mg being the standard dose for life-threatening bleeding. 1, 2

Dosing Based on Clinical Scenario

Severe/Life-Threatening Bleeding

  • 10 mg of vitamin K1 by slow intravenous infusion (over 30 minutes), administered simultaneously with prothrombin complex concentrate (PCC) 1, 2
  • May require additional doses every 12 hours based on INR response 3
  • For intravenous administration, maximum effect occurs within 6-12 hours 3

Significant but Non-Life-Threatening Bleeding

  • 5-10 mg of vitamin K1 intravenously 2, 4
  • Should be administered by slow infusion to reduce risk of anaphylactic reactions 1, 3

Excessive Anticoagulation Without Significant Bleeding

  • For INR 4.5-10 without significant bleeding: 1-2.5 mg oral vitamin K 3, 5
  • For INR >9 without significant bleeding: 3-5 mg oral vitamin K 3, 5
  • Example: For a nonbleeding patient with an INR of 9,2.5 mg phytonadione orally is appropriate 5

Route of Administration Considerations

Intravenous Administration

  • Provides more rapid correction of INR than oral route in the first 6-12 hours 6
  • At 6 hours, significantly more patients reach therapeutic INR range with IV compared to oral administration 6
  • Should be administered by slow infusion over at least 30 minutes to minimize risk of anaphylactic reactions 3, 2
  • Anaphylactic reactions occur in approximately 3 per 100,000 doses via a non-IgE mechanism 1

Oral Administration

  • By 24 hours, oral and IV routes achieve similar INR correction 6
  • Preferred over IV when immediate correction is not required, due to lower risk of anaphylactic reactions 7
  • Requires adequate GI absorption; avoid in patients with malabsorption 4
  • Bile salts must be given with tablets when endogenous bile supply is deficient 4

Important Clinical Considerations

Monitoring and Follow-up

  • INR should be monitored regularly after vitamin K administration 1, 4
  • The coagulant effects of phytonadione are not immediate; improvement of INR may take 1-8 hours 4
  • For severe bleeding, interim use of blood products (PCC or fresh frozen plasma) is necessary while waiting for vitamin K to take effect 1, 4

Potential Pitfalls

  • Doses exceeding 10 mg can prevent re-warfarinization for days and create a prothrombotic state 1, 3
  • Phytonadione is not a clotting agent; it works by enabling synthesis of vitamin K-dependent clotting factors 4
  • Subcutaneous administration is less effective than IV or oral routes; at 8 hours, mean INR decrease was only 0.4 with SC vs 3.4 with IV administration 8
  • In patients with liver disease, repeated large doses may not be effective if initial response is unsatisfactory 4

Special Populations

  • In cirrhotic patients, the clinical impact of vitamin K may be limited; a study showed only a 0.3 decrease in INR over 3 days with high-dose IV vitamin K 9
  • Elderly patients have higher bleeding risk at any given INR level and may require more cautious dosing 3, 2

Remember that vitamin K will not counteract the anticoagulant action of heparin or direct oral anticoagulants, and is specifically used for vitamin K antagonist reversal 1, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Warfarin Reversal in Significant Bleeding or Emergency Surgery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Duración de la Terapia con Vitamina K para Coagulopatía

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Management and dosing of warfarin therapy.

The American journal of medicine, 2000

Research

The use of vitamin K in patients on anticoagulant therapy: a practical guide.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.